Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAUG-2
- Development stage
- Preclinical
- Lead developer
- Portage Biotech
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
**SAUG-2** is a preclinical PORT-4 nanolipogel co-formulation for solid tumors. It is designed to co-deliver PD-1- and CTLA-4-directed immune-checkpoint components in a single tumor-targeted nanolipogel medicine, with the intended goal of enhancing antitumor immune responses while potentially limiting systemic exposure. Portage Biotech lists SAUG-2 as a preclinical solid-tumor program and holds a 70% economic interest in the PORT-4 candidates. ([portagebiotech.com](https://www.portagebiotech.com/our-portfolio/port-4-nanolipogel-formulations/))
- Other names
- PD-1-CTLA-4-nanolipogel co-formulationPD1-CTLA-4-nanolipogel co-formulationPD 1-CTLA-4-nanolipogel co-formulationNLG co-formulation
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SAUG-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAUG-2.